On August 5, 2026, the trial titled "Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial" was recorded with a status update involving glatiramer. The trial, registered under identifier NCT03500328, is listed with a phase designation of not applicable. Its current status is active, not recruiting, meaning enrollment of new participants has closed while the study continues.
This trial is part of ongoing research into approaches for treating multiple sclerosis. Glatiramer is an approved therapy included among the treatment strategies being evaluated in this study. No results have been posted as part of this update, and no efficacy or safety outcomes are described in the available event data.
The status change reflects the trial's progression through its registered timeline rather than any reported findings. Readers should note that "active, not recruiting" indicates the study is still underway, with existing participants continuing per the trial protocol.
For further details on the trial's design and objectives, readers can consult the official listing at ClinicalTrials.gov. For background on glatiramer as an approved compound, readers can refer to the compound overview.